Nonetheless, our findings highlight the potential for basal CDCA3 levels as a screening tool at initial biopsy for treatment naïve NSCLC patients, in a process similar to the current immunotherapy biomarker PD-L138. The gene discussed is CDCA3; the disease is non-small cell lung carcinoma.